<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144465</url>
  </required_header>
  <id_info>
    <org_study_id>noradrenaline vs phenylephrine</org_study_id>
    <nct_id>NCT04144465</nct_id>
  </id_info>
  <brief_title>Noradrenaline Infusion Versus Phenylephrine Infusion in Improving Serum Lactate Level in HIPEC</brief_title>
  <official_title>EFFECT OF NORADRENALINE INFUSION VERSUS PHENYLEPHRINE INFUSION IN IMPROVING ABG PARAMETERS IN HIPEC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suez Canal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suez Canal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABG PARAMETERS ARE CHANGED DURING HIPEC, WE TRIED TO FIND COMPARISON BETWEEN NORADRENALINE
      AND PHENYLEPHRINE IN OPTIMIZING ABG PARAMETERS THAT REFLECTS ORGAN PERFUSIONS ESPECIALLY
      SERUM LACTATE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arterial blood gas testing is considered one of the most important and widely used test in
      the detection of acidosis, alkalosis, electrolytes disturbance and tissue perfusion. in
      regard to tissue perfusion serum lactate above 4 mmol/L indicates poor tissue perfusion.
      serum lactate could be measured at ABG or separately. in this study we will test the effect
      of both noradrenaline and phenylephrine on lactate level at ABG during the stage of HIPAC in
      managing abdominal cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SERUM LACTATE IN ABG</measure>
    <time_frame>IMMEDIATELY POSTOPERATIVELY</time_frame>
    <description>LANDMARK FOR TISSUE AND ORGAN PERFUSION</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</condition>
  <arm_group>
    <arm_group_label>NORADRENALIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NORADRENALINE INFUSION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHENYLEPHRINE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PHENYLEPHRINE INFUSION</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NORADRENALIN</intervention_name>
    <description>DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION</description>
    <arm_group_label>NORADRENALIN</arm_group_label>
    <other_name>PERFUSION</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHENYLEPHRINE</intervention_name>
    <description>DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION</description>
    <arm_group_label>PHENYLEPHRINE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CANCER PATIENTS ENROLLED FOR HIPEC

        Exclusion Criteria:

          -  DRUG SENSITIVITY
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Khalid Hospital</name>
      <address>
        <city>NajrƒÅn</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suez Canal University</investigator_affiliation>
    <investigator_full_name>Abdelrhman Alshawadfy</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

